Pancreatic Cancer Research

ResearcherLouisiana State UniversityActive in the last 2 years

Omeed Moaven

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0560-0457; OpenAlex author ID A5045389785. Sources: OpenAlex.

Their work

Papers
14 (first author 0, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
30
Papers, trials and grants by year

2019: 2 papers · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: 2 papers · 2025: 2 papers · 2026: 7 papers

Papers 14

  1. Multimodal Care and Outcomes of Pancreatic Cancer Patients Are Influenced by Factors Beyond Biology: A Population-Based Study From Louisiana Tumor Registry. Last author DOI 10.1002/jso.70129↗
  2. Outcomes of Total Pancreatectomy Versus Pancreaticoduodenectomy for Surgical Management of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1002/jso.70260↗
  3. Nonlinear Modeling Reveals Novel Associations Between Genetically Predicted Protein Levels and Pancreatic Cancer Risk. Co-author DOI 10.1002/mc.70135↗
  4. The impact of the timing of adjuvant treatment initiation in patients with upfront resection of pancreatic cancer. Last author DOI 10.1016/j.suronc.2025.102329↗
  5. Integrative Proteomic Analysis Reveals VMG Oncolytic Virus–Induced Molecular Reprogramming in Pancreatic Ductal Adenocarcinoma Co-author DOI 10.21203/rs.3.rs-9943137/v1↗
  6. Comparative Proteomic Profiling of Responses to Standard Systemic Treatment Regimens in Pancreatic Cancer. Last author DOI 10.3390/cells15060531↗
  7. CMTM6-Silencing Microbial Immunotherapy Reprograms PDAC Tumors and Restores T-cell Function Co-author DOI 10.64898/2026.01.26.701790↗
  8. Racial Inequities in Receiving Neoadjuvant Treatment in Patients With Pancreatic Cancer Are Associated With Worse Outcomes in Louisiana. Last author DOI 10.1002/jso.27901↗
  9. Resistance signatures to oncolytic vesiculoviruses in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.omton.2025.200937↗
  10. Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target. Last author DOI 10.3389/fimmu.2024.1287459↗
  11. Enhancing Neoadjuvant Virotherapy's Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer. Co-author DOI 10.3390/biomedicines12071596↗
  12. Optimal Adjuvant Treatment Approach After Upfront Resection of Pancreatic Cancer: Revisiting the Role of Radiation Based on Pathologic Features. Co-author DOI 10.1097/sla.0000000000003770↗
  13. Healthcare disparities in outcomes of patients with resectable pancreatic cancer. Co-author DOI 10.1016/j.amjsurg.2018.12.007↗
  14. An invited commentary on "Postoperative outcomes in elderly patients undergoing pancreatic resection for pancreatic adenocarcinoma: A systematic review and met… Co-author DOI 10.1016/j.ijsu.2019.10.035↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bolni Marius Nagalo · 7 shared papers, 2024–2026 · strength 1.66
  2. Aimée Galatas · 3 shared papers, 2026 · strength 0.96
  3. Conner Daniel Hartupee · 4 shared papers, 2024–2026 · strength 0.90
  4. Chiswili Yves Chabu · 3 shared papers, 2024–2026 · strength 0.71
  5. Mitesh J. Borad · 3 shared papers, 2025–2026 · strength 0.70
  6. Ann M Byerley · 2 shared papers, 2026 · strength 0.65
  7. Sydney McManus · 2 shared papers, 2026 · strength 0.60
  8. John Lyons · 2 shared papers, 2025–2026 · strength 0.53
  9. Hannah R. Malinosky · 2 shared papers, 2025–2026 · strength 0.53
  10. Sudhakar Ammanamanchi · 2 shared papers, 2026 · strength 0.48
  11. Amirsalar Mansouri · 2 shared papers, 2026 · strength 0.48
  12. Jiří Adamec · 2 shared papers, 2026 · strength 0.48
  13. Khandoker Usran Ferdous · 2 shared papers, 2024–2025 · strength 0.39
  14. Kevin M. Sullivan · 1 shared paper, 2026 · strength 0.36
  15. Jingjing Zhu · 1 shared paper, 2026 · strength 0.33
  16. Hajime Yamazaki · 1 shared paper, 2026 · strength 0.33
  17. Lang Wu · 1 shared paper, 2026 · strength 0.33
  18. Mohammad A. Al Efishat · 1 shared paper, 2025 · strength 0.25
  19. Xiao‐Cheng Wu · 1 shared paper, 2025 · strength 0.25
  20. John H. Stewart · 1 shared paper, 2026 · strength 0.24
  21. Paul de Figueiredo · 1 shared paper, 2026 · strength 0.23
  22. Chelsae R Watters · 1 shared paper, 2025 · strength 0.22
  23. Michael T. Barrett · 1 shared paper, 2025 · strength 0.22
  24. Emmanouil Giorgakis · 1 shared paper, 2024 · strength 0.17
  25. Michail N. Mavros · 1 shared paper, 2024 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.